Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized by Both Fortune and Fierce Biotech as Pioneer in AI-Driven Drug Discovery

Verge Genomics, a clinical-stage, tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs for complex diseases, announced that Alice Zhang, CEO and co-founder of Verge Genomics, has been named to both Fortune’s 2022 40 Under 40 list of rising business influencers and Fierce Biotech’s list of the 2022 Fiercest Women in Life Sciences.

AI News: Infobip Creates AI-powered Chatbot for Uber

“The biotech startup phenotype is changing and so are its leaders”

“The biotech startup phenotype is changing and so are its leaders,” said Alice Zhang, CEO of Verge Genomics. “In an era where talent is the biggest bottleneck, those who adapt will find an untapped pool of creative minds, fresh ideas, and big returns. I am proud to be part of the transformation of biotech as we merge technology and science to improve the lives of patients.”

Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio

Fortune annually names 40 men and women under the age of 40 who are influential leaders in their industry. This year, Zhang was recognized in the health/bioscience category for leading Verge as it transforms drug discovery through the integration of AI and machine learning with human data to find better drugs, faster.

Each year Fierce spotlights women who are leading the way in life sciences. Zhang was selected not only for blazing trails in biopharma R&D, but also in corporate culture, leadership, and gender equity.

At a time when talent is one of the biggest bottlenecks to innovation, Zhang is changing the way biotech leaders look. As a co-founder and CEO, Zhang leads a team of scientists and engineers using technology to transform the drug discovery process. She epitomizes a new wave of first-time biotech CEOs leading ambitious, technology-driven biotech companies whose fresh perspectives are shifting not just the science but also how companies are built

Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1

 [To share your insights with us, please write to sghosh@martechseries.com]